Novo Nordisk adds Mars CEO as board observer
Source: SeekingAlpha
2026-03-26 11:57:16 ET
More on Novo Nordisk A/S
- Novo Nordisk: The Illusion Of Cheap
- Novo Nordisk - Enough Is Enough: 5 Reasons It's Time To Sell (Rating Downgrade)
- Novo Nordisk: Buying The Dip Before Volume Dominance
- Novo’s China obesity drug posts positive mid-stage trial results
- Novo Nordisk board proposes DKK 7.95 final dividend for 2025, initiates DKK 15B buyback
Read the full article on Seeking Alpha
For further details see:
Novo Nordisk adds Mars CEO as board observer
Hennes & Mauritz AB - Class B
NASDAQ: HMRZF
HMRZF Trading
0.0% G/L:
$16.80 Last:
252 Volume:
$16.80 Open:
